I2B (Inflammation, Immunopathology, Biotherapy) is a French initiative gathering different medical specialties with the objective to study and manage inflammatory and autoimmune diseases by integrating translational information. This project requires a strong collaboration between all the actors to share information and knowledge and a dedicated data management system capable of integrating this information. The members of the consortium are then involved in all the steps of the project, from data production to final analyses.
The consortium comprises 32 teams from 4 hospitals with 5 national center for rare diseases and 14 patient’s organizations. This initiative led to 12 clinical trials aiming at deepening the knowledge on autoimmune and inflammatory diseases, but also testing new promising molecules, results of the fundamental researches performed by the consortium.
Chronic inflammation, a condition present in various diseases including those with an immune component, is an important cause of morbidity/mortality in the developed world. A wide range of disorders fall into this disease category. These are rare or common disorders, whose best management requires an integrated approach, tightly linking clinicians from internal medicine or medical specialties to research teams with translational research programs in the field.
The rationale for the i2B is principally based on:
- The concept of the autoinflammatory/autoimmune disease continuum (AADC)
- The expected benefits of managing rare disorders together with common diseases
- The importance of the transition from pediatric to adult healthcare departments.
The i2B Consortium
I2B is a collegial network of 32 teams from 4 university hospitals (Pitie – Salpetriere, Saint – Antoine, Tenon and Trousseau) linked to the Universite Pierre et Marie Curie (UPMC).
These teams provide expertise in the biological and clinical aspects of inflammation, immunology, genetics, cell biology, systems biology and biotherapy. In addition, the complementary expertise of the 4 pediatric units (pneumonology, nephrology, medical genetics and neurology) and of the 9 departments of adult medicine (internal medicine, nephrology, gastroenterology, rheumatology, ophthalmology and pneumonology) cover the entire spectrum of the autoimmune autoinflammatory disease continuum (AADC).
I2B aims to strengthen existing links, stimulate new collaborations and promote cross-fertilization between disciplines so as to improve patient management.
The general objective is:
to better study and manage inflammatory and autoimmune diseases by integrating translational information. This will allow breaking down some artificial boundaries between these disorders through the study of important phenotypes that cut across diagnostic groups. This should lead to reconsider current disease classification schemes in the light of the AADC seen through various arms of the immune system.
The specific objectives are:
- to cross-phenotype inflammatory and autoimmune diseases,
- to discover and validate biomarkers and novel therapeutic targets,
- to develop and evaluate biotherapies based on this knowledge,
- to implement high-level teaching and training activities in the field.
For more information and the full project description please visit the project’s website at: https://dhu-i2b.fr